Inhaled Nitric Oxide Delivery Systems

Global Inhaled Nitric Oxide Delivery Systems Market to Reach US$864.8 Million by 2030

The global market for Inhaled Nitric Oxide Delivery Systems estimated at US$699.7 Million in the year 2024, is expected to reach US$864.8 Million by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Pediatric, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$610.3 Million by the end of the analysis period. Growth in the Adult segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$190.6 Million While China is Forecast to Grow at 6.8% CAGR

The Inhaled Nitric Oxide Delivery Systems market in the U.S. is estimated at US$190.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$174.6 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Inhaled Nitric Oxide Delivery Systems Market – Key Trends & Drivers Summarized

What Is Propelling the Demand for Inhaled Nitric Oxide Delivery Systems?

The market for inhaled nitric oxide (iNO) delivery systems is witnessing significant growth, driven by increasing applications in respiratory therapy and critical care. Inhaled nitric oxide is widely used as a selective pulmonary vasodilator, particularly in treating conditions such as persistent pulmonary hypertension of the newborn (PPHN), acute respiratory distress syndrome (ARDS), and hypoxic respiratory failure. The growing incidence of neonatal respiratory disorders and the rising number of preterm births have propelled the demand for advanced iNO delivery systems in neonatal intensive care units (NICUs). Additionally, the use of iNO therapy in adult critical care settings, particularly for patients with severe respiratory distress and pulmonary hypertension, has further expanded its market scope.

Another crucial factor driving market growth is the increasing adoption of iNO therapy in extracorporeal membrane oxygenation (ECMO) procedures. As ECMO therapy becomes a standard intervention for patients with severe cardiopulmonary failure, the integration of iNO delivery systems into ECMO circuits is gaining traction. The ability of inhaled nitric oxide to improve oxygenation and reduce pulmonary vascular resistance makes it a valuable adjunct therapy in ECMO-supported patients. Moreover, ongoing research into the potential applications of iNO for conditions such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, and COVID-19-induced respiratory complications is contributing to the growing demand for innovative iNO delivery technologies.

How Are Technological Innovations Enhancing Inhaled Nitric Oxide Delivery?

The evolution of iNO delivery systems is being shaped by significant technological advancements aimed at improving treatment precision, portability, and patient safety. One of the most notable innovations in this space is the development of compact and portable nitric oxide delivery devices. Traditional hospital-based iNO systems are being complemented by lightweight, mobile solutions that enable therapy administration in ambulatory and homecare settings. These portable devices are particularly beneficial for pediatric and adult patients requiring long-term iNO therapy for conditions such as pulmonary arterial hypertension (PAH) and fibrotic lung diseases. The shift towards decentralized care and home-based treatment solutions is expected to drive further advancements in portable iNO delivery technologies.

Another transformative trend in iNO delivery is the integration of smart monitoring and automation features. Next-generation iNO devices are equipped with real-time oxygenation monitoring, automated dose adjustment, and closed-loop control systems that optimize nitric oxide administration based on patient-specific needs. These intelligent systems reduce the risk of nitrogen dioxide (NO2) toxicity, ensuring safer and more effective therapy. Additionally, digital health technologies, including remote patient monitoring (RPM) and cloud-based data analytics, are being incorporated into iNO delivery systems, allowing clinicians to track treatment progress and adjust therapy parameters remotely. These advancements are enhancing patient outcomes while streamlining clinical workflows and reducing hospital burden.

What Are the Expanding Applications of iNO Therapy Beyond Traditional Uses?

While inhaled nitric oxide therapy has been primarily used in neonatal and critical care settings, its applications are expanding into new therapeutic areas, unlocking additional market opportunities. One emerging area of interest is the use of iNO for treating pulmonary complications associated with lung transplantation. Studies suggest that nitric oxide can reduce ischemia-reperfusion injury, improve graft function, and lower the risk of post-transplant pulmonary hypertension. As lung transplantation procedures increase worldwide, the demand for iNO therapy in perioperative and post-transplant care is expected to grow.

Another promising application is the potential use of iNO therapy in cardiology, particularly in treating heart failure with preserved ejection fraction (HFpEF) and right ventricular dysfunction. Nitric oxide’s vasodilatory effects can improve right heart function and pulmonary circulation, making it a valuable therapeutic option for heart failure patients with pulmonary hypertension. Additionally, ongoing clinical trials are evaluating the effectiveness of iNO in managing high-altitude pulmonary edema (HAPE), chronic thromboembolic pulmonary hypertension (CTEPH), and post-operative pulmonary complications. These emerging indications are creating new pathways for the development and commercialization of next-generation iNO delivery systems.

What Are the Key Growth Drivers Shaping the Future of the iNO Delivery Systems Market?

The growth in the inhaled nitric oxide delivery systems market is driven by several factors, including technological advancements, expanding therapeutic indications, and the increasing prevalence of respiratory and cardiovascular disorders. One of the primary drivers is the rising incidence of neonatal pulmonary disorders and the growing adoption of iNO therapy in NICUs. With premature birth rates on the rise, healthcare providers are investing in advanced iNO delivery systems to improve neonatal respiratory outcomes and reduce the risk of long-term complications.

Another key factor fueling market expansion is the increasing demand for iNO therapy in acute and chronic respiratory diseases. The COVID-19 pandemic highlighted the potential role of inhaled nitric oxide in improving oxygenation in patients with severe respiratory failure, leading to heightened research interest and investment in iNO delivery technologies. Additionally, the growing awareness of pulmonary hypertension and interstitial lung diseases is driving pharmaceutical companies to explore new formulations and device innovations to enhance iNO therapy’s efficacy and accessibility.

Regulatory advancements and industry collaborations are also shaping market growth. The U.S. Food and Drug Administration (FDA) and European regulatory bodies are actively supporting the development of novel iNO delivery systems, leading to the introduction of next-generation devices with improved safety and performance features. Furthermore, strategic partnerships between medical device companies, pharmaceutical firms, and research institutions are accelerating the commercialization of innovative iNO delivery solutions. The convergence of these factors is positioning the inhaled nitric oxide delivery systems market for sustained growth, with a strong emphasis on technological innovation, expanded clinical applications, and improved patient access to life-saving respiratory therapies.

SCOPE OF STUDY:

The report analyzes the Inhaled Nitric Oxide Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Pediatric, Adult); Product (Disposables, System); Application (Hypoxic Respiratory Failure, Acute Hypoxemic Respiratory Failure, Others); End-Use (Hospitals, Ambulatory Surgery Centers, Clinics)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Air Liquide Healthcare
• Bellerophon Therapeutics
• Beyond Air, Inc.
• BioLum Sciences
• Breeze Technologies
• Circassia Pharmaceuticals
• Cyclerion Therapeutics
• Getinge AB
• International Biomedical
• Linde plc
• Mallinckrodt Pharmaceuticals
• Medtronic plc
• NIOX Group plc
• NOxBOX Ltd.
• NU-MED Plus, Inc.
• Philips Healthcare
• SLE Ltd.
• SoundHealth
• VERO Biotech
• Zylo Therapeutics

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.